As the population ages, the prevalence of Alzheimer’s disease (AD) is expected to increase. But there is no real way to diagnose the disease and drugs currently on the market only treat the symptoms of Alzheimer’s.
At the same time, analysts say there is tremendous opportunity for pharmaceutical companies in this market, especially for companies that develop therapies that prevent neurological damage and cognitive decline. Drugs that can modify the disease will represent a breakthrough in this market.
AD is a progressive brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate, and carry out daily activities. There are four particular characteristics that define AD. They are: loss of neurons (especially cholinergic neurons); cortical atrophy, degeneration, or withering of cerebral cortex; presence of neurofibrillary tangles (NTs); and accumulation of neuritic plaques (NPs)…
About Alzheimer’s Disease
Alzheimer’s Disease Therapies Market Share
Experts on this Topic
Cheryl Barton, Ph.D. Analyst and Consultant to Espicom Business Intelligence, Princeton, N.J.; Espicom is a provider of independent and impartial market information with more than 25 years of continuous experience in the medical devices and pharmaceuticals markets. For more information, visit espicom.com.
Neil Buckholtz, Ph.D. Chief, Dementias of Aging Branch of the Neuroscience and Neuropsychology of Aging Program, National Institute on Aging, Bethesda, Md.; The National Institute on Aging (NIA) is one of 27 institutes and centers that constitute the National Institutes of Health; the NIA leads federal efforts to support and conduct basic, clinical, epidemiological, and social research on aging and the needs of older people. For more information, visit nia.nih.gov.
Eric Karran, Ph.D. Chief Scientific Officer, Neurodegenerative Diseases, Eli Lilly and Co., Indianapolis; Lilly is a leading, innovation-driven pharmaceutical company committed to developing best-in-class products that help people live longer, healthier, and more active lives. For more information, visit lilly.com.
Neil Kurtz, M.D. CEO and President, TorreyPines Therapeutics, La Jolla, Calif.; TorreyPines Therapeutics, formerly Neurogenetics Inc., is a biopharmaceutical company that discovers and develops breakthrough small-molecule drugs to treat diseases and disorders of the central nervous system. For more information, visit torreypinestherapeutics.com.
Naissan Vahman. Senior Analyst, Millennium Research Group, Toronto; Millennium Research Group is a provider of strategic information to the healthcare sector. For more information, visit mrg.net.
Andrea S. Witt, Ph.D. Analyst, Decision Resources Inc., Waltham, Mass; Decision Resources provides in-depth research on the trends, emerging developments, and market potential of the drug industry. For more information, visit decisionresources.com.